TABLE 5.
In vivo tumorigenicity test
| Publication | Transplanted cells | TPD50 | Matrigel | Transplanted animals | Reference |
|---|---|---|---|---|---|
| Kusakawa et al. | HeLa cells | 1.3 × 104 cells (at 16 weeks) | − | NOG mice | 99 |
| HeLa cells | 4.0 × 105 cells (at 16 weeks) | − | nude mice | ||
| HeLa cells | 7.9 × 10 cells (at 16 weeks) | + | NOG mice | ||
| Kanemura et al. | HeLa cells | 3.5 (Log10) (at 8 weeks) | + | nude mice | 100 |
| HeLa cells | 4.9 (Log10) (at 10 weeks) | − | nude mice | ||
| HeLa cells | 2.5 (Log10) (at 11 weeks) | + | SCID mice | ||
| HeLa cells | 3.83 (Log10) (at 11 weeks) | − | SCID mice | ||
| HeLa cells | 2.17 (Log10) (at 16 weeks) | + | NOD‐SCID mice | ||
| HeLa cells | 3.5 (Log10) (at 14 weeks) | − | NOD‐SCID mice | ||
| HeLa cells | 1.1 (Log10) (at 18 weeks) | + | NOG mice | ||
| HeLa cells | 3.97 (Log10) (at 13 weeks) | − | NOG mice | ||
| HeLa cells | 1.32 (Log10) (at 33 weeks) | − | nude rats | ||
| hiPSCs | 4.73 (Log10) (at 33 weeks) | − | nude rats | ||
| Yasuda et al. | hiPSC clumps | 6.8 × 102 cells (at 16 weeks) | − | NOG mice | 103 |
| Single hiPSCs and NHDF | 4.6 × 103 cells (at 16 weeks) | − | NOG mice | ||
| Single hiPSCs and NHDF+ROCK inhibitor | 6.3 × 102 cells (at 16 weeks) | − | NOG mice |
Abbreviations: NHDF, Normal human neonatal dermal fibroblasts; TPD50, tumor‐producing dose at the 50% endpoint.